22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Because the Nissan leadership scandal is about as well-contained as Chernobyl in the early days [tha...
Read More >
The blame and shame for the opioid-drug overdose crisis that kills tens of thousands Americans annua...
Read More >
The Federal Trade Commission (FTC) has announced increases to the notification thresholds under the ...
Read More >
Last week, the Department of Justice (“DOJ”) updated its Manual on Evaluation of Corporate Complia...
Read More >
On 23 October 2019, the UK Supreme Court decided that Professor Ian Shanks, a former employee of Uni...
Read More >
In early December, the United States District Court for the Southern District of New York denied, in...
Read More >